C-Type Natriuretic Peptide (CNP) (1-22), human TFA
Modify Date: 2024-01-12 16:58:33
C-Type Natriuretic Peptide (CNP) (1-22), human TFA structure
|
Common Name | C-Type Natriuretic Peptide (CNP) (1-22), human TFA | ||
|---|---|---|---|---|
| CAS Number | 1966153-17-2 | Molecular Weight | 2311.62 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C95H158F3N27O30S3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of C-Type Natriuretic Peptide (CNP) (1-22), human TFAC-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3]. |
| Name | C-Type Natriuretic Peptide (CNP) (1-22), human TFA |
|---|
| Description | C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
NPR-B |
| In Vitro | C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1]. PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]: Dose (nM/kg) AUC0→∞ (pM・min/mL) MRT0→∞ (min) T1/2 (min) CLtot (mL/min/kg) Vdss (mL/kg) 20 320±54 1.02±0.18 1.42±0.45 63.9±11.9 64.2±5.1 PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human (TFA)[1]: Dose (nM/kg) Cmax (pM/mL) Tmax (min) AUC0→∞ (pM・min/mL) MRT0→∞ (min) T1/2 (min) BA (%) 50 9.02±3.74 5.0±0.0 152±73 13.9±3.4 10.0±5.0 19±9 Each value represents the mean±SD of 3 rats. MRT=mean residence time, CLtot=total clearance, T1/2=half-life period, BA=bioavailability. i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[3]. |
| References |
| Molecular Formula | C95H158F3N27O30S3 |
|---|---|
| Molecular Weight | 2311.62 |